Second Sight Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- AI-linked earnings, Mideast deal hopes send Dow, S&P 500 to record highs
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Second Sight Medical (EYES) Reports In-Line Q3 EPS
November 14, 2019 4:12 PM ESTSecond Sight Medical (NASDAQ: EYES) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $472 thousand versus the consensus estimate of $940 thousand.
Recent Corporate Highlights:
Reached agreement with the U.S. Food and Drug Administration (FDA) regarding the primary efficacy endpoint to be used in the Orion® Visual Cortical Prosthesis System (Orion) pivotal trial;Presented additional positive data from the Companys Early Feasibility Study of Orion at three scientific conferences in October: the American Academy of Ophthalmology... More